ALLO
Price
$1.11
Change
+$0.03 (+2.75%)
Updated
Nov 3, 04:39 PM (EDT)
Capitalization
376.59M
2 days until earnings call
Intraday BUY SELL Signals
VYGR
Price
$1.80
Change
+$0.02 (+1.12%)
Updated
Nov 3, 04:32 PM (EDT)
Capitalization
109.68M
6 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ALLO vs VYGR

ALLO vs VYGR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ALLO vs. VYGR commentary
Nov 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a Buy and VYGR is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ALLO with price predictions
Nov 02, 2026

ALLO's RSI Oscillator is staying in oversold zone for 1 day

It is expected that a price bounce should occur soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +7.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALLO advanced for three days, in 187 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

ALLO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALLO as a result. In 74 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

The Moving Average Convergence Divergence Histogram (MACD) for ALLO turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 44 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALLO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for ALLO entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.863) is normal, around the industry mean (3.104). P/E Ratio (-1.652) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (91.743) is also within normal values, averaging (439.647).

The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. ALLO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALLO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for VYGR with price predictions
Nov 02, 2026

VYGR's RSI Oscillator climbs out of oversold territory

The RSI Indicator for VYGR moved out of oversold territory on November 02, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 26 of the 30 cases the stock moved higher. This puts the odds of a move higher at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for VYGR just turned positive on October 30, 2026. Looking at past instances where VYGR's MACD turned positive, the stock continued to rise in 38 of 45 cases over the following month. The odds of a continued upward trend are 84%.

Following a +15.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where VYGR advanced for three days, in 229 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

VYGR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VYGR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for VYGR entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.710) is normal, around the industry mean (3.104). P/E Ratio (-0.983) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.070) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (5.263) is also within normal values, averaging (439.647).

The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. VYGR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VYGR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
ALLO vs VYGR: Fundamental Ratings
ALLO
VYGR
OUTLOOK RATING
1..100
1370
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
48
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
8390
P/E GROWTH RATING
1..100
1312
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VYGR's Valuation (48) in the Biotechnology industry is in the same range as ALLO (49). This means that VYGR’s stock grew similarly to ALLO’s over the last 12 months.

VYGR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ALLO (100). This means that VYGR’s stock grew similarly to ALLO’s over the last 12 months.

ALLO's SMR Rating (97) in the Biotechnology industry is in the same range as VYGR (98). This means that ALLO’s stock grew similarly to VYGR’s over the last 12 months.

ALLO's Price Growth Rating (83) in the Biotechnology industry is in the same range as VYGR (90). This means that ALLO’s stock grew similarly to VYGR’s over the last 12 months.

VYGR's P/E Growth Rating (12) in the Biotechnology industry is in the same range as ALLO (13). This means that VYGR’s stock grew similarly to ALLO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLOVYGR
RSI
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 7 days ago
81%
Bullish Trend 15 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 5 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
71%
COMPARISON
Comparison
Nov 03, 2026
Stock price -- (ALLO: $1.09 vs. VYGR: $1.78)
Brand notoriety: ALLO and VYGR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 150% vs. VYGR: 149%
Market capitalization -- ALLO: $376.59M vs. VYGR: $109.68M
ALLO [@Biotechnology] is valued at $376.59M. VYGR’s [@Biotechnology] market capitalization is $109.68M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $140.2B. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 1 FA rating(s) are green while VYGR’s FA Score has 1 green FA rating(s).

  • ALLO’s FA Score: 1 green, 4 red.
  • VYGR’s FA Score: 1 green, 4 red.
According to our system of comparison, both ALLO and VYGR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 4 TA indicator(s) are bullish while VYGR’s TA Score has 5 bullish TA indicator(s).

  • ALLO’s TA Score: 4 bullish, 4 bearish.
  • VYGR’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, VYGR is a better buy in the short-term than ALLO.

Price Growth

ALLO (@Biotechnology) experienced а -9.92% price change this week, while VYGR (@Biotechnology) price change was +1.71% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.24%. For the same industry, the average monthly price growth was -12.18%, and the average quarterly price growth was -17.16%.

Reported Earning Dates

ALLO is expected to report earnings on Nov 05, 2026.

VYGR is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (-2.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ALLO
Daily Signal:
Gain/Loss:
VYGR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SCAP35.610.35
+0.99%
Infrastructure Capital Small Cap Income ETF (SCAP)
LOOM.X0.001817-0.000006
-0.34%
Loom Network cryptocurrency
CFX.X0.045507-0.000619
-1.34%
Conflux cryptocurrency
ALT.X0.005622-0.000108
-1.89%
Altlayer cryptocurrency
TNSR.X0.026840-0.001231
-4.39%
Tensor cryptocurrency